• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma.

作者信息

Mouhieddine Tarek H, Parekh Samir, Cho Hearn Jay, Richter Joshua, DeCastro Andrew, Shah Jatin, Landesman Yosef, Chari Ajai, Jagannath Sundar, Madduri Deepu

机构信息

Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.

Department of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, 10 East 102nd Street, 6th Floor, New York, NY, 10029, USA.

出版信息

Ann Hematol. 2021 Dec;100(12):3057-3060. doi: 10.1007/s00277-020-04293-y. Epub 2020 Oct 2.

DOI:10.1007/s00277-020-04293-y
PMID:33009581
Abstract
摘要

相似文献

1
Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma.塞利尼索、硼替佐米与地塞米松（SVD方案）用于多次治疗后的复发难治性多发性骨髓瘤
Ann Hematol. 2021 Dec;100(12):3057-3060. doi: 10.1007/s00277-020-04293-y. Epub 2020 Oct 2.
2
Selinexor, Bortezomib, and Dexamethasone for Heavily Pretreated Multiple Myeloma: A Case Series.塞利尼索、硼替佐米和地塞米松用于多次预处理的多发性骨髓瘤：病例系列
Clin Lymphoma Myeloma Leuk. 2020 Dec;20(12):e947-e955. doi: 10.1016/j.clml.2020.07.016. Epub 2020 Jul 29.
3
Selinexor for the treatment of patients with relapsed or refractory multiple myeloma.塞利尼索治疗复发或难治性多发性骨髓瘤患者。
J Oncol Pharm Pract. 2024 Apr;30(3):535-546. doi: 10.1177/10781552241235902. Epub 2024 Mar 8.
4
Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow-up subgroup analysis of the BOSTON trial.既往治疗对复发/难治性多发性骨髓瘤患者接受塞利尼索联合硼替佐米和地塞米松治疗结局的影响：BOSTON 试验的扩展随访亚组分析。
Eur J Haematol. 2024 Aug;113(2):242-252. doi: 10.1111/ejh.14223. Epub 2024 May 1.
5
Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone.接受塞利尼索、硼替佐米和地塞米松治疗的既往接受过治疗的多发性骨髓瘤患者的周围神经病变症状、疼痛及功能情况。
Am J Hematol. 2021 Oct 1;96(10):E383-E386. doi: 10.1002/ajh.26282. Epub 2021 Jul 12.
6
Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.塞利尼索、伊沙佐米和低剂量地塞米松用于复发或难治性多发性骨髓瘤患者的I期研究。
Clin Lymphoma Myeloma Leuk. 2020 Mar;20(3):198-200. doi: 10.1016/j.clml.2019.12.013. Epub 2019 Dec 26.
7
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.先前治疗对既往治疗的多发性骨髓瘤患者使用塞利尼索、硼替佐米和地塞米松的影响。
J Hematol Oncol. 2021 Apr 13;14(1):59. doi: 10.1186/s13045-021-01071-9.
8
Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.每周一次塞利尼索、硼替佐米和地塞米松治疗复发或难治性多发性骨髓瘤的成本效益。
Leuk Lymphoma. 2021 Nov;62(11):2777-2784. doi: 10.1080/10428194.2021.1933477. Epub 2021 Jun 21.
9
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.塞利尼索、硼替佐米和地塞米松与硼替佐米和地塞米松治疗既往多发性骨髓瘤：细胞遗传学风险的结果。
Am J Hematol. 2021 Sep 1;96(9):1120-1130. doi: 10.1002/ajh.26261. Epub 2021 Jul 5.
10
Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, nonrandomized, multicenter GEM-SELIBORDARA study.塞利尼索、达雷妥尤单抗、硼替佐米和地塞米松治疗复发或难治性多发性骨髓瘤患者：II 期、非随机、多中心 GEM-SELIBORDARA 研究结果。
Haematologica. 2024 Jul 1;109(7):2219-2228. doi: 10.3324/haematol.2023.284089.

引用本文的文献

1
Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients.塞利尼索、硼替佐米与地塞米松：一种用于多次治疗的骨髓瘤患者的有效挽救方案。
Onco Targets Ther. 2022 Mar 14;15:243-250. doi: 10.2147/OTT.S341120. eCollection 2022.
2
Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor.多发性骨髓瘤治疗中免疫治疗之外的新型方法：美法仑氟芬、维奈克拉和塞利尼索的案例
Front Oncol. 2021 Sep 30;11:716751. doi: 10.3389/fonc.2021.716751. eCollection 2021.